🇺🇸 Mycophenoate Mofetil in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 9

Most-reported reactions

1. Cough — 1 report (11.11%)
2. Diabetic Ketoacidosis — 1 report (11.11%)
3. Dyspnoea — 1 report (11.11%)
4. Insomnia — 1 report (11.11%)
5. Laryngospasm — 1 report (11.11%)
6. Memory Impairment — 1 report (11.11%)
7. Nervousness — 1 report (11.11%)
8. Psychomotor Hyperactivity — 1 report (11.11%)
9. Swollen Tongue — 1 report (11.11%)

Source database →

Frequently asked questions

Is Mycophenoate Mofetil approved in United States?

Mycophenoate Mofetil does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Mycophenoate Mofetil in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.